These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24755548)

  • 1. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
    Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
    PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
    PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
    Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
    Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
    Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
    J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.
    Lu G; Chang JT; Liu Z; Chen Y; Li M; Zhu JJ
    Mol Neurobiol; 2016 Nov; 53(9):6511-6525. PubMed ID: 26614510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
    Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
    World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GNG5 is an unfavourable independent prognostic indicator of gliomas.
    Yang B; Han ZY; Wang WJ; Ma YB; Chu SH
    J Cell Mol Med; 2020 Nov; 24(21):12873-12878. PubMed ID: 33000557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
    Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
    Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.
    Yan W; Zhang W; You G; Zhang J; Han L; Bao Z; Wang Y; Liu Y; Jiang C; Kang C; You Y; Jiang T
    Neuro Oncol; 2012 Dec; 14(12):1432-40. PubMed ID: 23090983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
    Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
    Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of diffuse gliomas.
    Jakovlevs A; Vanags A; Gardovskis J; Strumfa I
    Pol J Pathol; 2019; 70(4):246-258. PubMed ID: 32146793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
    You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
    CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.
    Zhang JX; Han L; Bao ZS; Wang YY; Chen LY; Yan W; Yu SZ; Pu PY; Liu N; You YP; Jiang T; Kang CS;
    Neuro Oncol; 2013 Dec; 15(12):1595-603. PubMed ID: 24203894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.
    Natesh K; Bhosale D; Desai A; Chandrika G; Pujari R; Jagtap J; Chugh A; Ranade D; Shastry P
    Neoplasia; 2015 Feb; 17(2):225-37. PubMed ID: 25748242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
    Szeliga M
    Neurochem Int; 2022 Feb; 153():105256. PubMed ID: 34968631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
    Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
    PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.
    Trabelsi S; Chabchoub I; Ksira I; Karmeni N; Mama N; Kanoun S; Burford A; Jury A; Mackay A; Popov S; Bouaouina N; Ben Ahmed S; Mokni M; Tlili K; Krifa H; Yacoubi MT; Jones C; Saad A; H'mida Ben Brahim D
    Mol Neurobiol; 2017 May; 54(4):2381-2394. PubMed ID: 26957305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
    Nutt CL; Mani DR; Betensky RA; Tamayo P; Cairncross JG; Ladd C; Pohl U; Hartmann C; McLaughlin ME; Batchelor TT; Black PM; von Deimling A; Pomeroy SL; Golub TR; Louis DN
    Cancer Res; 2003 Apr; 63(7):1602-7. PubMed ID: 12670911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The landscape of the mesenchymal signature in brain tumours.
    Behnan J; Finocchiaro G; Hanna G
    Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.